ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of TTK inhibitor, CFI-402257
December 01, 2021Treadwell Therapeutics, a clinical stage biotechnology company developing novel therapeutics for highly aggressive cancers, today announced that the U.S. Food and Drug Administration (FDA) ... -
Treadwell initiates expansion of cohorts in phase 1 study of CFI-402257
September 01, 2020Treadwell Therapeutics announced the initiation of three expansion cohorts in its ongoing Phase 1 study evaluating CFI-402257, a selective and highly potent oral inhibitor of tyrosine threonine kinase (TTK).
Pharma Sources Insight January 2025
